id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S16583 R69647 |
Battino (Epilepsy), 2024 | Major congenital malformations (MCMs) | early pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.52 [0.03;8.48] C | 0/31 110/3,584 | 110 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S17213 R72104 |
The Australian Pregnancy Register of Antiepileptic Drugs (Mixed indications) (Controls exposed to LTG), 2024 | Major congenital malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
6.27 [0.25;158.67] C excluded (control group) |
0/2 20/406 | 20 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S17214 R72106 |
The Australian Pregnancy Register of Antiepileptic Drugs (Mixed indications) (Controls unexposed, sick), 2024 | Major congenital malformations | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 8.87 [0.33;236.26] C | 0/2 7/207 | 7 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S17194 R72052 |
The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls exposed to Lamotrigine), 2024 | Major congenital malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.94 [0.11;81.30] C excluded (control group) |
0/6 1/50 | 1 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S17195 R72062 |
The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls unexposed, sick), 2024 | Major congenital malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.78 [0.09;33.62] C | 0/6 16/340 | 16 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S16193 R67086 |
The NAAED (Controls exposed to LTG) (Indications NOS), 2024 | Major congenital malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.25 [0.02;4.05] C excluded (control group) |
0/93 52/2,461 | 52 | 93 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S16183 R67075 |
The NAAED (Controls unexposed, disease free) (Indications NOS), 2024 | Major congenital malformations | 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No | 0.45 [0.03;7.61] C | 0/93 15/1,311 | 15 | 93 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S17186 R72034 |
The UKIEPR (Epilepsy) (Controls exposed to Lamotrigine), 2024 | Major malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
4.60 [0.24;86.58] C excluded (control group) |
0/5 49/2,098 | 49 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S17187 R72036 |
The UKIEPR (Epilepsy) (Controls unexposed, sick), 2024 | Major malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 4.34 [0.22;84.74] C | 0/5 13/541 | 13 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S17217 R72112 |
The West China Registry (Epilepsy) (Controls exposed to LTG), 2024 | Major congenital malformation | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
8.33 [0.15;473.61] C excluded (control group) |
0/5 0/38 | 0 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S17218 R72114 |
The West China Registry (Epilepsy) (Controls unexposed, sick), 2024 | Major congenital malformation | during pregnancy (anytime or not specified) excluded | prospective cohort | unexposed, sick | Adjustment: No |
3.64 [0.18;73.84] C excluded (exposition period) |
0/5 7/253 | 7 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 1.55 [0.41;5.79] | 161 | 137 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Epilepsy; 2: Mixed indications) (Controls unexposed, sick; 3: Epilepsy) (Controls unexposed, sick; 4: Controls unexposed, disease free) (Indications NOS; 5: Epilepsy) (Controls unexposed, sick;
Asymetry test p-value = 0.0343 (by Egger's regression)
slope=-18.3265 (5.0817); intercept=12.4893 (3.3772); t=3.6981; p=0.0343
excluded 17213, 17194, 16193, 17186, 17217